FDx Advisors Inc. Sells 620 Shares of Kenvue Inc. (NYSE:KVUE)

FDx Advisors Inc. cut its position in Kenvue Inc. (NYSE:KVUE) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,721 shares of the company’s stock after selling 620 shares during the quarter. FDx Advisors Inc.’s holdings in Kenvue were worth $293,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Morningstar Investment Management LLC raised its holdings in Kenvue by 30.8% in the fourth quarter. Morningstar Investment Management LLC now owns 12,392 shares of the company’s stock worth $265,000 after purchasing an additional 2,919 shares in the last quarter. First Bank & Trust grew its stake in shares of Kenvue by 3.4% during the fourth quarter. First Bank & Trust now owns 94,234 shares of the company’s stock worth $2,012,000 after acquiring an additional 3,127 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after acquiring an additional 21,222 shares during the last quarter. Sunpointe LLC purchased a new stake in shares of Kenvue during the fourth quarter worth about $207,000. Finally, Ieq Capital LLC grew its stake in shares of Kenvue by 20.0% during the fourth quarter. Ieq Capital LLC now owns 12,853 shares of the company’s stock worth $274,000 after acquiring an additional 2,146 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $22.38 on Friday. The business has a 50-day moving average of $21.29 and a 200 day moving average of $22.14. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a market capitalization of $42.90 billion, a price-to-earnings ratio of 42.22, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.66%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KVUE. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Finally, UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.